OTCQB: PHRRF | CSE: PHRM
PharmaTher Holdings Ltd. Ketamine
  • HOME
  • COMPANY
    • Management
    • Board Of Directors
  • PRODUCTS
    • KetaVault
    • KETARX Ketamine
  • INVESTORS
  • NEWS
  • CONTACT
  • HOME
  • COMPANY
    • Management
    • Board Of Directors
  • PRODUCTS
    • KetaVault
    • KETARX Ketamine
  • INVESTORS
  • NEWS
  • CONTACT

KetaVault™​

KetaVault™ is a world-first portal offering pharmaceutical and biotech companies, academic and clinical researchers, and government agencies direct access to PharmaTher's comprehensive proprietary data on ketamine. KetaVault™ is strategically designed to streamline and accelerate clinical trials, regulatory submissions, and commercialization initiatives for ketamine-based therapies.
KetaVault™ underscores PharmaTher’s leadership in the ketamine space, fostering high-value partnerships that could drive revenue growth and expand market opportunities.

KetaVault™: A Gateway to Expedited Ketamine Development

KetaVault™ provides partners with a significant competitive advantage by offering insights derived from years of dedicated research. This can directly support:
  • Expedited Regulatory Pathways: Leverage existing data to potentially streamline new drug applications and emergency use authorizations.
  • De-risked Clinical Development: Inform trial design and identify promising indications based on robust existing research.
  • Enhanced Commercial Strategy: Gain insights into manufacturing, control, and product development for market readiness.

Key Proprietary Information Available in KetaVault™ Includes:
  • Regulatory Filings: Investigational New Drug (IND) Applications.
  • Comprehensive Drug Information: Investigator’s Brochures.
  • Manufacturing Insights: Chemistry, Manufacturing, and Control (CMC) data.
  • Clinical Research & Data: In-depth clinical study protocols and research data for indications including Parkinson’s disease.
  • Orphan Drug Designations: Access to information supporting FDA Orphan Drug Approvals for Amyotrophic Lateral Sclerosis, Rett Syndrome, Complex Regional Pain Syndrome, Status Epilepticus, and ischemia/reperfusion injury during solid organ transplantation.
  • Novel Delivery Systems: Product development programs and regulatory filings for PharmaTher's ketamine microneedle patch and subcutaneous wearable pump.

Beyond Data: Comprehensive Partnership Support
​

In addition to data access, PharmaTher offers to support partners' clinical and commercialization initiatives with a reliable supply of ketamine, manufactured in the USA under the FDA’s stringent cGMP guidelines. This integrated offering positions PharmaTher as an end-to-end partner in the rapidly growing ketamine market.

    Interested in partnering?

Submit

Connect With Us

Picture
Picture
PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario  Canada
M5C 1P1
Psychedelic Pharmaceuticals
© COPYRIGHT 2025.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.